Combination Encorafenib Plus Binimetinib in Patients With Melanoma

October 17, 2018
Paolo A. Ascierto, MD

Paolo A. Ascierto, MD, discusses how results from the COLUMBUS trial affect the treatment landscape for patients with BRAF-mutant melanoma.

Paolo A. Ascierto, MD, director of the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy at the National Tumor Institute Fondazione G. Pascale in Naples, discusses how results from the COLUMBUS trial affect the treatment landscape for patients withBRAF-mutant melanoma.

Ascierto recommends choosing the combination encorafenib (Braftovi) plus binimetinib (Mektovi). While the efficacy appeared similar to other treatments, encorafenib may be considered the “best” BRAF inhibitor.